ClinicalTrials.gg
RecruitingNCT07694375Updated Aug 6, 2026

A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

A Phase 2 interventional study of Ophthalmic solution (matching formulation without ascorbic acid) and Ascorbic acid ophthalmic solution 5% in Corneal Endothelial Cell Loss and Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery, sponsored by Caravel Oculus Pty Ltd. Recruiting at 8 sites in Australia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Caravel Oculus Pty Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study is designed to assess whether an investigational eye drop called CA201A can help protect the cornea (the outer covering of the eye) and reduce damage to corneal endothelial cells following cataract surgery, without causing significant side effects. Cataract surgery is one of the common surgical procedures, however, it can sometimes lead to a loss of corneal endothelial cells, which are essential for maintaining the corneal clarity and long-term eye health.

About 200 adults in Australia who are scheduled to have cataract surgery will be enrolled in this study following eligibility check. All eligible participants will be randomly assigned (by chance) to receive either the CA201A eye drops or a similar eye drop without the active ingredient. Neither the participant nor the study doctor will know the treatment each participant is receiving until the study is completed.

All enrolled participants will place 1 drop of CA201A four times daily, starting 7 days prior to the surgery, continue on the day of surgery, and then keep using them for 4 weeks following surgery. After treatment, participants will be followed for up to 12 weeks after surgery in order to monitor safety and assess how well the treatment works.

All participants will undergo standard cataract surgery and receive usual care; the study eye drops will be given in addition to this routine treatment. Throughout the study, doctors will measure changes in corneal endothelial cell density and perform other eye examinations to evaluate the treatment effect.

Read the detailed description

This is a multicenter, randomized, double-masked, vehicle-controlled, parallel-arm, Phase 2 study designed to evaluate the safety and efficacy of CA201A, a 5% ascorbic acid ophthalmic solution, for the prevention of corneal endothelial cell loss in subjects undergoing cataract surgery.

The study consists of three periods:

  • Screening Period: Up to 23 days before the Baseline \& treatment visit (Day -7)
  • Treatment Period: Subjects will self-administer the study intervention (CA201A or vehicle) topically to the study eye, one drop four times daily (QID), beginning on Day -7 and continuing through Day 28 post-surgery. On the day of surgery (Day 0), dosing should be administered prior to surgery according to the scheduled regimen. Postoperative dosing on Day 0 may be delayed or omitted if the operated eye is padded or covered immediately following surgery, in accordance with standard surgical practice. Study intervention should be resumed as soon as clinically appropriate.
  • Follow-up Period: Participants will be followed through Week 12 (day 84 ± 5 days) post-surgery for assessment of safety and efficacy endpoints.

Eligible participants planning to undergo cataract extraction by phacoemulsification will be randomized in a 1:1 ratio to one of two treatment arms. Study treatment will begin 7 days prior to cataract surgery, continue on the day of surgery, and be maintained for 4 weeks postoperatively. All participants will undergo standard-of-care phacoemulsification cataract surgery. The study intervention is administered in addition to usual perioperative management.

Surgical procedures will reflect routine clinical care, with protocol-specified documentation of key intra-operative parameters (e.g., cumulative dissipated energy, ultrasound time, irrigation volume, and intra-operative complications) to support interpretability of endothelial cell outcomes. The expected duration of participation for each participant is approximately 12 weeks post-surgery (up to approximately 16 weeks including screening).

02

Conditions studied

  • Corneal Endothelial Cell Loss
  • Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery

Keywords

  • cataract surgery
  • corneal endothelial cell loss
03

In context

Corneal Endothelial Cell Loss

28 studies on the registry are indexed under Corneal Endothelial Cell Loss; 6 are open to participants now.

This study's planned enrollment of 200 is above the median of 50 across 16 interventional studies indexed under Corneal Endothelial Cell Loss.

Browse Corneal Endothelial Cell Loss studies →

Lead sponsor

This is the only study on the registry with Caravel Oculus Pty Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must voluntarily sign and date a Human Research Ethics Committee (HREC) approved form (ICF) prior to the initiation of any screening or study-specific procedures.
  • In the Investigator's opinion, the subject is willing and able to comply with study instructions and complete all scheduled study visits.
  • Male or female aged ≥18 and ≤85 years.
  • Scheduled to undergo cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens.
  • Has the potential to improve best-corrected visual acuity (BCVA) in the study eye following surgery, as judged by the Investigator.
  • Has a nuclear cataract exhibiting a nuclear opalescence of Grade 3, 4, or 5 in the study eye according to the Lens Opacities Classification System III (LOCS III) classification. This includes pure nuclear cataracts as well as mixed-type cataracts (ie, nuclear opalescence grade 3 to 5 with or without co-existing cortical and/or posterior subcapsular opacities).
  • Has corneal endothelium in the study eye that can be adequately assessed using specular microscopy, with sufficient image quality for endothelial cell density analysis.
  • Has a central corneal ECD ≥1000 cells/mm² in the study eye at the Screening visit, as measured by specular microscopy.
  • Has a pinhole visual acuity of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (approximately equivalent to 6/60 Snellen) in the study eye at the Screening visit, measured using an ETDRS chart at 4 meters. The fellow eye must have visual acuity sufficient, in the opinion of the Investigator, to allow safe postoperative function.
  • Female subjects must be of nonchildbearing potential or have a negative pregnancy test at Screening and agree to use appropriate throughout the study.
  • Male subjects with female partners of must agree to use appropriate contraception and refrain from sperm donation during the study.

Exclusion criteria

Exclusion Criteria:

  • Ocular Exclusions (Study Eye):
  • Active or disease that, in the opinion of the Investigator, could affect ocular surface integrity.
  • Active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to impair wound healing.
  • Intraocular pressure (IOP) ≤6 mmHg in either eye at screening.
  • Fuchs' endothelial corneal dystrophy (Grade 4 or higher on clinical examination).
  • History of corneal transplantation or other corneal surgery.
  • History of intraocular surgery in the study eye within 6 months of screening (except YAG laser capsulotomy >3 months prior to screening).
  • Planned combined cataract surgery with other intraocular procedures (eg, glaucoma surgery, vitrectomy).
  • Active ocular infection or inflammation in either eye.
  • Uncontrolled glaucoma (intraocular pressure >25 mmHg on maximum tolerated medical therapy) in the study eye.
  • Significant corneal opacity, scarring, or irregularity that would interfere with accurate specular microscopy assessment (including cases where image acquisition or analysis is not feasible).
  • History of uveitis or other chronic inflammatory eye disease in the study eye.
  • Proliferative diabetic retinopathy or active retinal disease in the study eye, that in the Investigator's opinion, may increase surgical risk or confound postoperative assessments.
  • Any other ocular condition that, in the opinion of the Investigator, may interfere with study assessments or subject safety.
  • History of corneal or retinal surgery (laser or incisional) in the study eye within 6 months, or planned ocular surgery during the study period.
  • Presence of severe corneal guttae or other abnormalities in the study eye that, in the opinion of the Investigator, preclude reliable endothelial cell assessment by specular microscopy.
  • Anticipated complex cataract surgery in the study eye that, in the opinion of the Investigator, is likely to substantially increase endothelial injury risk or require nonstandard surgical techniques (eg, brunescent or hypermature cataract, significant zonular instability requiring planned capsular support devices, or other features expected to materially prolong phacoemulsification).
  • Specular microscopy images that are not gradable at Screening despite repeat acquisition attempts.
  • Systemic Exclusions:
  • Known to ascorbic acid or any component of the study drug or vehicle.
  • Current use of systemic ascorbic acid supplementation (oral or intravenous) >500 mg/day (Subjects taking ≤500 mg/day may continue their current regimen).
  • History of calcium oxalate nephrolithiasis (kidney stones) within the past 5 years.
  • Severe renal impairment (estimated \<30mL/min/1.73 m²).
  • Known glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with clinically significant hemolytic risk.
  • Pregnant or breastfeeding women.
  • Females of unwilling to use acceptable .
  • Participation in another interventional clinical study or use of an product within 6 weeks or 5 half-lives (whichever is longer) prior to study treatment. Observational studies and the use of over-the-counter vitamins or supplements are not exclusionary.
  • Medical or psychiatric conditions that, in the opinion of the Investigator, would make consistent follow-up unlikely or pose an unacceptable medical risk.
  • Clinically significant abnormalities in screening laboratory assessments (hematology, serum chemistry, or urinalysis), that, in the opinion of the Investigator, render the subject unsuitable for participation.

In general, subjects will be excluded if any of the following are present at screening:

  • (ALT) or aspartate aminotransferase (AST) >2.5 × (ULN)
  • Total >1.5 × ULN (unless consistent with Gilbert's syndrome)
  • Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² Laboratory abnormalities not meeting the above thresholds may still be considered exclusionary if deemed clinically significant by the Investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Placebo comparator
    Vehicle (placebo)

    Arm 1: Vehicle (placebo) ophthalmic solution - one drop 4 times daily (QID)

    Drug: Ophthalmic solution (matching formulation without ascorbic acid)

  • Experimental
    Treatment (CA201A)

    Arm 2: CA201A ophthalmic solution one drop QID

    Drug: Ascorbic acid ophthalmic solution 5%

Interventions

  • DrugOphthalmic solution (matching formulation without ascorbic acid)

    Vehicle (placebo) ophthalmic solution (matching formulation without ascorbic acid)

  • Arm 2 - CA201A (ascorbic acid ophthalmic solution 5%)

06

What researchers measure

Primary outcomes

  1. Change in central corneal endothelial cell density associated with cataract surgery

    Change from baseline in central corneal endothelial cell density (cells/mm²) in the study eye, measured by specular microscopy in the central corneal region

    Time frame: Visit 1: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

Secondary outcomes

  1. Incidence and Severity of Treatment Emergent Adverse Events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Safety and tolerability will be evaluated in terms of treatment emergent AEs and serious adverse events. This includes the types, incidence, and severity of TEAEs.

    Time frame: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

  2. Change From Baseline in Best-Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) letter score

    Safety and tolerability will be evaluated in terms of change from baseline in BCVA

    Time frame: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

  3. Incidence of Corneal Oedema Assessed by Slit Lamp Biomicroscopy

    The presence and incidence of corneal oedema in the study eye will be evaluated using slit lamp biomicroscopy.

    Time frame: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

  4. Intraocular Pressure (IOP) Measurements

    Intraocular pressure (mmHg) will be measured in the study eye using standard tonometry methods.

    Time frame: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

  5. Corneal endothelial cell morphology

    Changes from baseline in corneal endothelial cell morphology parameters (coefficient of variation in cell size and percentage of hexagonal cells) will be assessed in the study eye.

    Time frame: Day -7 ± 2 (Baseline), Week 6 (Day 42 ± 3), and Week 12 (Day 84 ± 5) post-surgery

  6. Corneal endothelial thickness

    Changes from baseline in central corneal thickness (CCT; in microns)

    Time frame: Day -7 ± 2 (Baseline) to Week 12 (Day 84 ± 5) post-surgery

  7. Postoperative Ocular Inflammation and Endothelial Outcomes

    Postoperative ocular inflammation and endothelial outcomes will be assessed by evaluating the proportion of participants with absence of anterior chamber cells and flare (Grade 0), clinical cure (absence of both cells and flare)

    Time frame: Week 1 (Day 7 ± 2) to Week 12 (Day 84 ± 5)

07

Study locations

2 of 8 sites recruiting
  • Canberra Eye Surgeons
    Deakin, Australian Capital Territory 2600, Australia
    Not yet recruiting
  • Nexus Eye Care Norwest
    Baulkham Hills, New South Wales 2153, Australia
    Not yet recruiting
    • Dr Anagha Vaze · Contactanagha.vaze@gmail.com · +61435539976
    • Prof Chameen Samarawickrama · Principal investigator
  • Nexus Eye Care Blacktown
    Blacktown, New South Wales 2148, Australia
    Not yet recruiting
    • Dr Anagha Vaze · Contactanagha.vaze@gmail.com · +61435539976
    • Prof Chameen Samarawickrama · Principal investigator
  • Eastwood Eye Specialists
    Eastwood, New South Wales 2122, Australia
    Recruiting
  • Sydney Retina Clinic & Day Surgery
    Sydney, New South Wales 2000, Australia
    Recruiting
  • Adelaide Eye and Retina Centre
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
    • A/Prof Jagjit Gilhotra · Contactjsgilhotra@gmail.com
    • A/Prof Jagjit Gilhotra · Principal investigator
  • Hobart Eye Surgeons
    Hobart, Tasmania 7000, Australia
    Not yet recruiting
  • Launceston Eye Doctors
    Launceston, Tasmania 7250, Australia
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 10, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07694375
Lead sponsor
Caravel Oculus Pty Ltd
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 28, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Sandy Lai
Contact
sandylai@caraveloculus.com
+886227119697 ext. 26

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion